
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc's focus on transforming metabolic disease treatment into durable, disease-modifying therapies is backed by significant market trends, as evidenced by a staggering 587% increase in prescriptions for GLP-1 drugs from 2019 to 2024. The company's upcoming FIH Phase 1 trial and anticipated scalable manufacturing capabilities suggest robust growth potential, particularly in response to the notable increase in prescriptions for GLP-1 therapies among individuals without a T2D diagnosis, which surged by approximately 1,961%. Furthermore, positive clinical data indicating improved blood glucose control and a favorable lipid profile position Fractyl Health to capitalize on the expanding market for innovative diabetes and obesity treatments, reflecting a strong foundation for future financial performance.
Bears say
Fractyl Health faces significant challenges regarding its cash burn rate, which could increase due to the expansion of its development and commercial programs, thus raising concerns over its ability to secure sufficient capital for ongoing platform development. The company's therapeutic approach remains hindered by the fundamental physiological challenges associated with type 2 diabetes (T2D), including a gradual loss of β-cell function that diminishes the effectiveness of their treatments. Additionally, research indicates potential inefficacies in its GLP-1 related therapies, with significantly lower circulating levels compared to pharmacologic alternatives, which may compromise the company's long-term viability and investor confidence.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares